PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: Dr Martens Puts Best Foot Forward

Wed, 03rd Feb 2021 10:50

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Wednesday.

----------

SMALL-CAP - WINNERS

----------

Dr Martens, 452.16p, up 22% from initial public offering price of 370p. The iconic boot maker said its entire share capital has begun trading on London's Main Market on Wednesday, with a market value of around GBP4.5 billion putting Dr Martens easily in contention for a spot in the FTSE 250 index of mid-caps.

----------

Volution Group, up 5.5% at 308.57 pence, 12-month range 122.46p-313p. The ventilation products supplier said it is "pleased" with its strong trading performance and also has agreed to buy Swedish ventilation equipment maker Nordiska Klimatfabriken.

----------

STV Group up 5.0% at 347.56p, 12-month range, 210p-452.83p. The Glasgow-based television broadcaster said it saw a record-breaking performance in January for its free streaming service STV Player, with the release of exclusive drama box sets driving viewer growth. STV said total steams for STV Player are up over 100% to 12.5 million streams when compared to a year prior. The number of monthly active users on the service grew by 20% in January.

----------

Standard Life Investments Property, up 4.9% at 60.80p, 12-month range 43.51p-993p. The property investor said net asset value per share as at December 31 was up 4.1% to 82.0p from 78.8p.

----------

4D Pharma, up 4.6% at 120.83p, 12-month range 23.5p-183p. The pharmaceutical company said enrolment is progressing well both for part B of the MRx0518 and Keytruda combination study and for its pancreatic cancer study. 4D said 24 additional patients across five active US sites have been treated in part B of the study, consisting of 12 patients with renal cell carcinoma, 9 patients with non-small cell lung cancer, and 3 bladder cancer patients.

----------

SMALL-CAP - LOSERS

----------

Bacanora Lithium, down 15% at 47.40p, 12-month range 14.5p-69p. The lithium explorer said it successfully raised approximately USD65 million through the placing of shares as well as a retail offer. A total of 101.4 million shares were placed at 45 pence each, raising proceeds of about USD62 million, while an extra USD3 million was raised after retail and other investors subscribed for 5.6 million shares.

----------

Porvair, down 2.5% at 525.75p, 12-month range 370p-796.47p. The filtration, laboratory and environmental technology firm's shares were continuing to fall after it said earlier this week that near-term trading remains unpredictable and continued to withhold earnings guidance. The stock is down 8.4% since last Thursday.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 May 2022 11:07

IN BRIEF: 4D Pharma rises as asthma drug moves on to part B of trial

4D Pharma PLC - Leeds, England-based pharmaceutical company - Says part A of the phase I/II trial of MRx-4DP0004 for the treatment of asthma showed that a greater amount of patients receiving the drug than those receiving placebo experienced a reduction in asthma control questionnaire scores. Reports that a greater proportion of the MRx-4DP0004 group than the placebo group experienced a reduction in the total weekly use of rescue medication at all time points. Adds that 50% of patients receiving the drug experienced "clinically meaningful" improvements in asthma quality of life questionnaire scores. Says MRx-4DP0004 is progressing to part B of the trial. Plans to enrol asthma patients with more symptomatic disease. Expects this to give a greater scope for treatment effects to be observed.

Read more
1 Apr 2022 09:56

AIM WINNERS & LOSERS: Quiz shares in style as sales top expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
1 Apr 2022 08:11

IN BRIEF: 4D Pharma annual pretax loss widens, sees itself well-funded

4D Pharma PLC - Leeds, England-based pharmaceutical company - Posts widened pretax loss for 2021. Pretax loss stretches to GBP57.5 million from GBP30.3 million the year before.

Read more
23 Mar 2022 11:21

AIM WINNERS & LOSERS: RWS and James Cropper sink on profit warnings

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
23 Mar 2022 11:16

4d Pharma shares jump on positive results from cancer treatment study

(Alliance News) - 4d Pharma PLC shares soared on Wednesday after the company said that its phase I/II study for the combination of MRx0518 and Keytruda for the treatment of renal cell carcinoma showed positive results.

Read more
9 Mar 2022 19:26

IN BRIEF: 4D Pharma registers for potential ADS offering in US

4D Pharma PLC - Leeds, England-based pharmaceutical company - Files shelf registration statement to the US Securities & Exchange Commission following which the company may offer up to USD150.0 million of shares in the form of American Depositary Shares, with each ADS reflecting eight ordinary shares.

Read more
22 Feb 2022 21:57

TRADING UPDATES: Angling Direct ups revenue; Ceiba takes Omicron hit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Feb 2022 09:55

4d Pharma gets FDA clearance for potential Parkinson's treatments

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced on Tuesday that the United States Food and Drug Administration (FDA) has cleared investigational new drug applications for 'MRx0005' and 'MRx0029', for the treatment of Parkinson's disease.

Read more
27 Jan 2022 13:20

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial

Read more
4 Jan 2022 10:32

IN BRIEF: 4d Pharma names John Doyle as new chief financial officer

IN BRIEF: 4d Pharma names John Doyle as new chief financial officer

Read more
13 Dec 2021 10:55

4D Pharma announces positive results in asthma treatment trials

4D Pharma announces positive results in asthma treatment trials

Read more
30 Sep 2021 11:05

4D Pharma pretax loss grows in first half after Spac merger costs

4D Pharma pretax loss grows in first half after Spac merger costs

Read more
29 Jul 2021 22:08

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

Read more
26 Jul 2021 16:23

EXECUTIVE CHANGES: Persimmon finance boss retires; Block fights Forest

EXECUTIVE CHANGES: Persimmon finance boss retires; Block fights Forest

Read more
4 Jun 2021 10:32

4D Pharma halts enrolment for Covid treatment trial, focuses on asthma

4D Pharma halts enrolment for Covid treatment trial, focuses on asthma

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.